

**AMENDMENTS TO THE SPECIFICATION**

Please amend the bridging paragraph at pages 17-18 as follows:

Desiccated HA (modal Mr  $8.9 \times 10^5$  k  $8.9 \times 10^5$  Da) was added to a portion of the 24.5mg/ml MTX stock solution and dissolved overnight with vortexing, to give a final concentration of 21mg/ml. To ensure sterility gentamicin was added to a concentration of 50 $\mu$ g/ml and incubated overnight at 4°C. Following the addition of [ $^3$ H]methotrexate the HA/MTX stock mixture was diluted to injection concentration with injection grade sodium chloride. Injections were individually made according to mouse body masses, to deliver 15mg/kg MTX and 12.5mg/kg HA in 50 $\mu$ l. With this quantity of HA injected into the body, saturation kinetics would be observed for the period of the experiment (Fraser *et al.*, 1983).

Please amend the paragraph at page 29, line 28 through page 30, line 3, as follows:

Desiccated HA (modal Mr  $8.9 \times 10^5$  k  $8.9 \times 10^5$  Da) is added to a portion of the 24.5mg/ml paclitaxel stock solution and dissolved overnight with vortexing, to give a final concentration of 21mg/ml. To ensure sterility gentamicin is added to a concentration of 50 $\mu$ g/ml and incubated overnight at 4°C. Following the addition of [ $^3$ H]paclitaxel the HA/paclitaxel stock mixture is diluted to injection concentration with injection grade sodium chloride. Injections are individually made according to mouse body masses, to deliver 15mg/kg paclitaxel and 12.5mg/kg HA in 50 $\mu$ l. With this quantity of HA injected into the body, saturation kinetics would be observed for the period of the experiment (Fraser *et al.*, 1983).

Please amend the paragraph at page 39, line 30 through page 40, line 4, as follows:

A stock of HA solution (10 $\mu$ M, 7mg/ml) was prepared by dissolving desiccated HA (modal Mr  $7 \times 10^5$  Da [[kDa]],) in 0.9% w/v pyrogen-free injection grade NaCl. To ensure a homogenous solution the HA was dissolved overnight at 4°C followed by thorough vortexing. To ensure that the HA had maintained its molecular weight during the preparation of the stock solution, the solution was analysed on a Sephadex S-1000 size exclusion gel with column - 40 specifications of 1.6cm x 70cm, sample size 2ml, flow rate 18.1/h and 2ml fraction size. The HA

was used at a final concentration of 1000nm, with all dilutions made in the appropriate growth medium.